A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus.

Abstract

In a double-blind, parallel-group, multicenter comparative trial in 127 evaluable patients with chronic, localized atopic dermatitis or lichen simplex chronicus, healing was reported in a higher percentage of patients treated with halobetasol propionate ointment than in those in the clobetasol propionate treatment group (65.1% versus 54.7%). The success rates (described as "healed" and "marked improvement") were practically identical in the two treatment groups (93.7% versus 92.2%). Early onset of therapeutic effect, that is, within 3 days of the start of treatment, was similar in the two treatment groups (24% versus 28%). Both preparations were well tolerated. Adverse effects were reported in 5% and 2% of the patients treated with halobetasol propionate and clobetasol propionate ointments, respectively.

• Authors: B Datz, S Yawalkar
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 25 Issue 6 Pt 2 Pg. 1157-60 (Dec 1991) ISSN: 0190-9622 [Print] United States
• PMID: 1757608 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Ointments
• Vasoconstrictor Agents
• halobetasol
• Clobetasol

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Chronic Disease
• Clobetasol (administration & dosage, analogs & derivatives, therapeutic use)
• Dermatitis, Atopic (drug therapy)
• Double-Blind Method
• Female
• Germany
• Humans
• Male
• Middle Aged
• Neurodermatitis (drug therapy)
• Ointments
• Patient Satisfaction
• Remission Induction
• Vasoconstrictor Agents (administration & dosage, therapeutic use)
• Wound Healing